UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-K ____________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 ____________ BioMarin Pharmaceutical Inc. (Exact name of registrant as specified in its charter) _ ...

BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q4 2020 Earnings Conference Call February 25, 2021 4:30 PM ET Company Participants Traci McCarty – Vice President of Investor Relations J.J. Bienaime – Chairman and Chief Executive Officer Jeff Ajer – Executive Vice President and Chief Commercial Officer Hank Fuchs – President, Worldwide Research and Development Brian Mueller – Executive Vice President and Chief Financial Officer Conference Call Participants Kripa Devarakonda – Truist Securities Cory Kasimov – JPMor ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q3 2020 Earnings Conference Call November 5, 2020 4:30 PM ET Company Participants Traci McCarty - VP, IR Jean-Jacques Bienaimé - Chairman and CEO Greg Guyer - EVP and Chief Technical Officer Jeff Ajer - EVP and CCO Henry Fuchs - President, Worldwide Research and Development Brian Mueller - EVP, CFO Conference Call Participants Salveen Richter - Goldman Sachs Cory Kasimov - JPMorgan Robyn Karnauskas - SunTrust Securities Chris Raymond - Piper Sandler Martin Auster - ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . | --- | --- | --- | |-------------------------------- ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q2 2020 Results Earnings Conference Call August 4, 2020 4:30 PM ET Company Participants Traci McCarty - Vice President, Investor Relations Jean-Jacques Bienaimé - Chairman and Chief Executive Officer Robert Baffi - President of Global Manufacturing and Technical Operations Jeff Ajer - Executive Vice President and Chief Commercial Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Executive Vice President, Chief Financial Officer Con ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

Table of Contents Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 BMRN The Nasdaq Global Select Market ______________________________________ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________________________ Form 10-Q ______________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANG ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2020 Earnings Conference Call April 29, 2020 4:15 PM ET Company Participants Traci McCarty - Vice President, Investor Relations Jean-Jacques Bienaimé - Chairman and Chief Executive Officer Robert Baffi - President of Global Manufacturing and Technical Operations Jeff Ajer - Executive Vice President and Chief Commercial Officer Henry Fuchs - President, Worldwide Research and Development Brian Mueller - Acting Chief Financial Officer Conference Call Participants R ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________ Form 10-K ____________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission file number: 000-26727 ____________ BioMarin Pharmaceutical Inc. (Registrant's telephone number, including area code) Sec ...

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN) Q4 2019 Earnings Conference Call February 26, 2020 4:30 PM ET Company Participants Traci McCarty - VP, IR Jean-Jacques Bienaimé - Chairman & CEO Jeffrey Ajer - EVP & Chief Commercial Officer Henry Fuchs - President, Worldwide Research & Development Brian Mueller - SVP, Finance, Acting CFO & CAO Robert Baffi - President, Global Manufacturing & Technical Operations Conference Call Participants Philip Nadeau - Cowen and Company Andrea Tan - Goldman Sachs Group Cory K ...